EraCal Therapeutics

EraCal Therapeutics develops a novel class of appetite suppressors to fight obesity

Today millions of people are obese. At the individual level, obesity reduces life expectancy by 3-4 years causing complications such as type 2 diabetes, psychosocial disorders, cancers among many others. Therapeutic options for weight loss exist in the form of lifestyle therapyweight-lowering drugs and/or bariatric surgeries depending on the disease severity and complications. Unfortunately, all offer a poor benefit/risk ratio to reduce obesity and to prevent the onset of obesity-associated complications.

EraCal’s platform enables unbiased and large-scale in vivo drug discovery in zebrafish larvae. The journal Science Advances published part of EraCal’s translational proof of concept. Such phenotypic strategies are capable of identifying novel mechanisms of actions and, consequently, are a prime choice to discover first-in-class drugs.

Find out more
www.eracal.ch
https://ch.linkedin.com/company/eracal-therapeutics
-
-

Sign In

Register

Reset Password

Please enter your username or email address, you will receive a link to create a new password via email.